Discuss the latest research findings on melanoma causation, susceptibility, epidemiology, as well as the importance of prevention and early diagnosis |
|
|
|
|
|
Demonstrate an understanding of clinically important breakthroughs in melanoma genetics and genomics, including the emerging role of molecular testing on therapy decisions |
|
|
|
|
|
Describe the role of normal and mutated BRAF in intracellular signaling and explain the rationale for BRAF and MEK inhibition in the treatment of melanoma |
|
|
|
|
|
Assess the impact of new therapies on overall survival in metastatic melanoma |
|
|
|
|
|
Describe the process of T-cell activation and checkpoints to control T-cell activity |
|
|
|
|
|
Identify the 4 patterns of response to immunotherapy and apply new immune-related response criteria (irRC) |
|
|
|
|
|
Monitor for and promptly treat immune-related adverse events (IRAEs) in patients taking newer therapies for metastatic melanoma |
|
|
|
|
|
Evaluate ongoing investigations of treatments for metastatic melanoma, including optimizing patient selection for clinical trials. |
|
|
|
|
|